An investigation of binding interactions of tumor-targeted peptide conjugated polyphenols with the kinase domain of ephrin B4 and B2 receptors

[1]  Aiping Lu,et al.  ADMETlab 2.0: an integrated online platform for accurate and comprehensive predictions of ADMET properties , 2021, Nucleic Acids Res..

[2]  Mélaine A. Kuenemann,et al.  New machine learning and physics-based scoring functions for drug discovery , 2021, Scientific Reports.

[3]  I. Provazník,et al.  In silico screening and molecular dynamics of phytochemicals from Indian cuisine against SARS-CoV-2 MPro , 2020, Journal of biomolecular structure & dynamics.

[4]  Neelam Sharma,et al.  AntiCP 2.0: an updated model for predicting anticancer peptides. , 2020, Briefings in bioinformatics.

[5]  B. Aderibigbe,et al.  Cinnamic Acid Derivatives and Their Biological Efficacy , 2020, International journal of molecular sciences.

[6]  R. Gomaa,et al.  Quinazoline Based HSP90 Inhibitors: Synthesis, Modeling Study and ADME Calculations Towards Breast Cancer Targeting. , 2020, Bioorganic & medicinal chemistry letters.

[7]  V. Shukla,et al.  An ayurvedic perspective along with in silico study of the drugs for the management of SARS-CoV-2 , 2020, Journal of Ayurveda and Integrative Medicine.

[8]  Keunwan Park,et al.  Evolutionary chemical binding similarity approach integrated with 3D-QSAR method for effective virtual screening , 2020, BMC Bioinformatics.

[9]  Yan Li,et al.  Therapeutic effects of ephrin B receptor 2 inhibitors screened by molecular docking on cutaneous squamous cell carcinoma , 2020, The Journal of dermatological treatment.

[10]  Laurent Emmanuel Dardenne,et al.  Highly Flexible Ligand Docking: Benchmarking of the DockThor Program on the LEADS-PEP Protein-Peptide Data Set , 2020, J. Chem. Inf. Model..

[11]  W. Catalona,et al.  EPHB4 inhibition activates ER stress to promote immunogenic cell death of prostate cancer cells , 2019, Cell Death & Disease.

[12]  Pedro H M Torres,et al.  Key Topics in Molecular Docking for Drug Design , 2019, International journal of molecular sciences.

[13]  P. W. Janes,et al.  Eph receptor signalling: from catalytic to non-catalytic functions , 2019, Oncogene.

[14]  Gergana Gocheva,et al.  A Look at Receptor-Ligand Pairs for Active-Targeting Drug Delivery from Crystallographic and Molecular Dynamics Perspectives. , 2019, Molecular pharmaceutics.

[15]  Zheng Gao,et al.  Assessing the performance of three resveratrol in binding with SIRT1 by molecular dynamics simulation and MM/GBSA methods: the weakest binding of resveratrol 3 to SIRT1 triggers a possibility of dissociation from its binding site , 2019, Journal of Computer-Aided Molecular Design.

[16]  Friedrich Rippmann,et al.  Avoiding hERG-liability in drug design via synergetic combinations of different (Q)SAR methodologies and data sources: a case study in an industrial setting , 2019, Journal of Cheminformatics.

[17]  Eric P. Winer,et al.  Breast Cancer Treatment: A Review , 2019, JAMA.

[18]  L. Alisaraie,et al.  Drug metabolites and their effects on the development of adverse reactions: Revisiting Lipinski’s Rule of Five , 2018, International journal of pharmaceutics.

[19]  B. Kuster,et al.  NVP‐BHG712: Effects of Regioisomers on the Affinity and Selectivity toward the EPHrin Family , 2018, ChemMedChem.

[20]  S. Joshi,et al.  In silico binding affinity studies of N-9 substituted 6-(4-(4-propoxyphenyl)piperazin-1-yl)-9H-purine derivatives-Target for P70-S6K1 & PI3K-δ kinases , 2018 .

[21]  Yanmin Zhang,et al.  Targeting receptor tyrosine kinase EphB4 in cancer therapy. , 2017, Seminars in cancer biology.

[22]  Olivier Michielin,et al.  SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules , 2017, Scientific Reports.

[23]  X. Zhang,et al.  Ferulic acid exerts antitumor activity and inhibits metastasis in breast cancer cells by regulating epithelial to mesenchymal transition. , 2016, Oncology reports.

[24]  Janez Konc,et al.  Computational Drug Repositioning by Target Hopping: A Use Case in Chagas Disease. , 2016, Current pharmaceutical design.

[25]  F. Jin,et al.  Gallic acid induces apoptosis and enhances the anticancer effects of cisplatin in human small cell lung cancer H446 cell line via the ROS-dependent mitochondrial apoptotic pathway. , 2016, Oncology reports.

[26]  Yacine Benguerba,et al.  Dehydration of natural gas using choline chloride based deep eutectic solvents: COSMO-RS prediction , 2016 .

[27]  S. Zahler,et al.  Three stories on Eph kinase inhibitors: From in silico discovery to in vivo validation. , 2016, European journal of medicinal chemistry.

[28]  B. Lesyng,et al.  Cinnamic Acid Derivatives as Inhibitors of Oncogenic Protein Kinases--Structure, Mechanisms and Biomedical Effects. , 2016, Current medicinal chemistry.

[29]  Y. Gilad,et al.  Synthesis, biological studies and molecular dynamics of new anticancer RGD-based peptide conjugates for targeted drug delivery. , 2016, Bioorganic & medicinal chemistry.

[30]  Jie Huang,et al.  Erythropoietin Stimulates Tumor Growth via EphB4. , 2015, Cancer cell.

[31]  Hwangseo Park,et al.  Computational prediction of octanol-water partition coefficient based on the extended solvent-contact model. , 2015, Journal of molecular graphics & modelling.

[32]  Mohammad Imran Siddiqi,et al.  Identification of Novel Inhibitors of Mycobacterium tuberculosis PknG Using Pharmacophore Based Virtual Screening, Docking, Molecular Dynamics Simulation, and Their Biological Evaluation , 2015, J. Chem. Inf. Model..

[33]  Xiaoxiong Zeng,et al.  Polymer nanoparticles composed with gallic acid grafted chitosan and bioactive peptides combined antioxidant, anticancer activities and improved delivery property for labile polyphenols , 2015 .

[34]  Botao Fa,et al.  Pi-pi Stacking Mediated Cooperative Mechanism for Human Cytochrome P450 3A4 , 2015, Molecules.

[35]  Yang Zhang,et al.  I-TASSER server: new development for protein structure and function predictions , 2015, Nucleic Acids Res..

[36]  Michael Schroeder,et al.  PLIP: fully automated protein–ligand interaction profiler , 2015, Nucleic Acids Res..

[37]  S. Genheden,et al.  The MM/PBSA and MM/GBSA methods to estimate ligand-binding affinities , 2015, Expert opinion on drug discovery.

[38]  Lakshmi Ptv,et al.  ACPP: A Web Server for Prediction and Design of Anti-cancer Peptides , 2015, International Journal of Peptide Research and Therapeutics.

[39]  T. Nakagawa,et al.  Multitargeting strategy using lenvatinib and golvatinib: Maximizing anti-angiogenesis activity in a preclinical cancer model , 2015, Cancer science.

[40]  Yang Zhang,et al.  The I-TASSER Suite: protein structure and function prediction , 2014, Nature Methods.

[41]  Helio J. C. Barbosa,et al.  A dynamic niching genetic algorithm strategy for docking highly flexible ligands , 2014, Inf. Sci..

[42]  J. Guzman,et al.  Natural Cinnamic Acids, Synthetic Derivatives and Hybrids with Antimicrobial Activity , 2014, Molecules.

[43]  Olivier Michielin,et al.  iLOGP: A Simple, Robust, and Efficient Description of n-Octanol/Water Partition Coefficient for Drug Design Using the GB/SA Approach , 2014, J. Chem. Inf. Model..

[44]  R. Nussinov,et al.  Promiscuous and specific recognition among ephrins and Eph receptors. , 2014, Biochimica et biophysica acta.

[45]  J. Brennecke,et al.  Excess enthalpy of monoethanolamine + ionic liquid mixtures: how good are COSMO-RS predictions? , 2014, The journal of physical chemistry. B.

[46]  T. Attwood,et al.  Completing the structural family portrait of the human EphB tyrosine kinase domains , 2014, Protein science : a publication of the Protein Society.

[47]  A. Andres,et al.  Overexpression of EphB4 in the mammary epithelium shifts the differentiation pathway of progenitor cells and promotes branching activity and vascularization , 2014, Development, growth & differentiation.

[48]  Stefano Mariani,et al.  Surface plasmon resonance applications in clinical analysis , 2014, Analytical and Bioanalytical Chemistry.

[49]  G. Batist,et al.  Role of the EphB2 receptor in autophagy, apoptosis and invasion in human breast cancer cells. , 2014, Experimental cell research.

[50]  M. Incerti,et al.  Target Hopping as a Useful Tool for the Identification of Novel EphA2 Protein–Protein Antagonists , 2014, ChemMedChem.

[51]  A. Misra,et al.  Epidermal growth factor receptor targeting in cancer: a review of trends and strategies. , 2013, Biomaterials.

[52]  A. Iafrate,et al.  The EphB4 Receptor Tyrosine Kinase Promotes Lung Cancer Growth: A Potential Novel Therapeutic Target , 2013, PloS one.

[53]  Sagar H. Barage,et al.  Molecular Dynamics Simulation and Molecular Docking Studies of Angiotensin Converting Enzyme with Inhibitor Lisinopril and Amyloid Beta Peptide , 2013, The Protein Journal.

[54]  C. Jeong,et al.  Antiangiogenic Effects of P‐Coumaric Acid in Human Endothelial Cells , 2013, Phytotherapy research : PTR.

[55]  Wei Zhu,et al.  Bioavailability and pharmacokinetics of genistein: mechanistic studies on its ADME. , 2012, Anti-cancer agents in medicinal chemistry.

[56]  Bianca Villavicencio,et al.  Recent Progress of Molecular Docking Simulations Applied to Development of Drugs , 2012 .

[57]  R. Noberini,et al.  Inhibition of Eph receptor-ephrin ligand interaction by tea polyphenols. , 2012, Pharmacological research.

[58]  Jianxing Song,et al.  Protein dynamics at Eph receptor-ligand interfaces as revealed by crystallography, NMR and MD simulations , 2012, BMC biophysics.

[59]  L. Flammini,et al.  Polyphenol rich botanicals used as food supplements interfere with EphA2-ephrinA1 system. , 2011, Pharmacological Research.

[60]  Huijun Sun,et al.  Molecular modeling study of checkpoint kinase 1 inhibitors by multiple docking strategies and prime/MM–GBSA calculation , 2011, J. Comput. Chem..

[61]  D. Cross,et al.  Inhibitors of the tyrosine kinase EphB4. Part 4: Discovery and optimization of a benzylic alcohol series. , 2011, Bioorganic & medicinal chemistry letters.

[62]  P. De,et al.  Cinnamic acid derivatives as anticancer agents-a review. , 2011, Current medicinal chemistry.

[63]  M. Incerti,et al.  Lithocholic Acid Is an Eph-ephrin Ligand Interfering with Eph-kinase Activation , 2011, PloS one.

[64]  S. Karthikeyan,et al.  Inhibitory effect of caffeic acid on cancer cell proliferation by oxidative mechanism in human HT-1080 fibrosarcoma cell line , 2011, Molecular and Cellular Biochemistry.

[65]  S. Mittal,et al.  Emerging strategies for EphA2 receptor targeting for cancer therapeutics , 2011, Expert opinion on therapeutic targets.

[66]  S. Borstnar,et al.  Triple negative breast cancer – prognostic factors and survival , 2010, Radiology and oncology.

[67]  Bert L. de Groot,et al.  Ligand docking and binding site analysis with PyMOL and Autodock/Vina , 2010, J. Comput. Aided Mol. Des..

[68]  Santhosh K. P. Kumar,et al.  Novel EphB4 monoclonal antibodies modulate angiogenesis and inhibit tumor growth. , 2010, The American journal of pathology.

[69]  R. Sharan,et al.  I-TASSER: a unified platform for automated protein structure and function prediction , 2010, Nature Protocols.

[70]  M. Breccia,et al.  Nilotinib: a second-generation tyrosine kinase inhibitor for chronic myeloid leukemia. , 2010, Leukemia research.

[71]  T. Nakagawa,et al.  E7050: A dual c‐Met and VEGFR‐2 tyrosine kinase inhibitor promotes tumor regression and prolongs survival in mouse xenograft models , 2010, Cancer science.

[72]  S. Goueli,et al.  ADP-Glo: A Bioluminescent and homogeneous ADP monitoring assay for kinases. , 2009, Assay and drug development technologies.

[73]  A. Caflisch,et al.  Structure-based optimization of potent and selective inhibitors of the tyrosine kinase erythropoietin producing human hepatocellular carcinoma receptor B4 (EphB4). , 2009, Journal of medicinal chemistry.

[74]  Bingding Huang,et al.  MetaPocket: a meta approach to improve protein ligand binding site prediction. , 2009, Omics : a journal of integrative biology.

[75]  Sirlester A. Parker,et al.  Structural recognition of an optimized substrate for the ephrin family of receptor tyrosine kinases , 2009, The FEBS journal.

[76]  Nathanael S Gray,et al.  Discovery and structural analysis of Eph receptor tyrosine kinase inhibitors. , 2009, Bioorganic & medicinal chemistry letters.

[77]  A. Olson,et al.  AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading , 2009, J. Comput. Chem..

[78]  Xiangrong Song,et al.  Preparation and characterization of folate conjugated N-trimethyl chitosan nanoparticles as protein carrier targeting folate receptor: in vitro studies , 2009, Journal of drug targeting.

[79]  A. Caflisch,et al.  Structure‐based tailoring of compound libraries for high‐throughput screening: Discovery of novel EphB4 kinase inhibitors , 2008, Proteins.

[80]  T. Pawson,et al.  Effects of dasatinib on EphA2 receptor tyrosine kinase activity and downstream signalling in pancreatic cancer , 2008, British Journal of Cancer.

[81]  Jon Read,et al.  Inhibitors of the tyrosine kinase EphB4. Part 1: Structure-based design and optimization of a series of 2,4-bis-anilinopyrimidines. , 2008, Bioorganic & medicinal chemistry letters.

[82]  J. D. Stuart,et al.  Design and effective synthesis of novel templates, 3,7-diphenyl-4-amino-thieno and furo-[3,2-c]pyridines as protein kinase inhibitors and in vitro evaluation targeting angiogenetic kinases. , 2007, Bioorganic & medicinal chemistry letters.

[83]  M. Deavers,et al.  The receptor tyrosine kinase EphB4 is overexpressed in ovarian cancer, provides survival signals and predicts poor outcome , 2007, British Journal of Cancer.

[84]  A. Chakrabarty,et al.  Cupredoxin-cancer interrelationship: azurin binding with EphB2, interference in EphB2 tyrosine phosphorylation, and inhibition of cancer growth. , 2007, Biochemistry.

[85]  Tingjun Hou,et al.  ADME Evaluation in Drug Discovery, 6. Can Oral Bioavailability in Humans Be Effectively Predicted by Simple Molecular Property-Based Rules? , 2007, J. Chem. Inf. Model..

[86]  Peter J McCormick,et al.  EphB2 and EphB4 receptors forward signaling promotes SDF-1-induced endothelial cell chemotaxis and branching remodeling. , 2006, Blood.

[87]  Santhosh K. P. Kumar,et al.  Receptor tyrosine kinase EphB4 is a survival factor in breast cancer. , 2006, The American journal of pathology.

[88]  Andrew I Su,et al.  An efficient rapid system for profiling the cellular activities of molecular libraries. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[89]  P. Kuhn,et al.  Structure and thermodynamic characterization of the EphB4/Ephrin-B2 antagonist peptide complex reveals the determinants for receptor specificity. , 2006, Structure.

[90]  Sean Ekins,et al.  Computational prediction of human drug metabolism , 2005, Expert opinion on drug metabolism & toxicology.

[91]  Noritaka Tokui,et al.  Designing scaffolds of peptides for phage display libraries. , 2005, Journal of bioscience and bioengineering.

[92]  Elena B Pasquale,et al.  EphB Receptor-binding Peptides Identified by Phage Display Enable Design of an Antagonist with Ephrin-like Affinity* , 2005, Journal of Biological Chemistry.

[93]  Y. Martin,et al.  A bioavailability score. , 2005, Journal of medicinal chemistry.

[94]  A. Middelberg,et al.  Estimating the potential refolding yield of recombinant proteins expressed as inclusion bodies , 2004, Biotechnology and bioengineering.

[95]  Paul Polakis,et al.  EphB2 as a Therapeutic Antibody Drug Target for the Treatment of Colorectal Cancer , 2004, Cancer Research.

[96]  W. Guida,et al.  Docking studies and model development of tea polyphenol proteasome inhibitors: Applications to rational drug design , 2003, Proteins.

[97]  K. Kullander,et al.  Mechanisms and functions of eph and ephrin signalling , 2002, Nature Reviews Molecular Cell Biology.

[98]  Jin Chen,et al.  The ephrins and Eph receptors in angiogenesis. , 2002, Cytokine & growth factor reviews.

[99]  T. Pawson,et al.  Structural Basis for Autoinhibition of the EphB2 Receptor Tyrosine Kinase by the Unphosphorylated Juxtamembrane Region , 2001, Cell.

[100]  John Hodgson,et al.  ADMET—turning chemicals into drugs , 2001, Nature Biotechnology.

[101]  E. Offord,et al.  Comparison of the antioxidant activity of commonly consumed polyphenolic beverages (coffee, cocoa, and tea) prepared per cup serving. , 2001, Journal of agricultural and food chemistry.

[102]  J. Sühnel,et al.  C-h⋯π-interactions in proteins , 2001 .

[103]  A. Goldberg,et al.  Why Does Threonine, and Not Serine, Function as the Active Site Nucleophile in Proteasomes?* , 2000, The Journal of Biological Chemistry.

[104]  Y. Tanigawara.  Role of P-glycoprotein in drug disposition. , 2000, Therapeutic drug monitoring.

[105]  T. Lybrand,et al.  Streptavidin-biotin binding energetics. , 1999, Biomolecular engineering.

[106]  A. Andres,et al.  Cell-type specific and estrogen dependent expression of the receptor tyrosine kinase EphB4 and its ligand ephrin-B2 during mammary gland morphogenesis. , 1998, Journal of cell science.

[107]  Y. Imai,et al.  Point mutations at threonine-301 modify substrate specificity of rabbit liver microsomal cytochromes P-450 (laurate (ω-1)-hydroxylase and testosterone 16α-hydroxylase) , 1989 .

[108]  R. Doolittle,et al.  A simple method for displaying the hydropathic character of a protein. , 1982, Journal of molecular biology.

[109]  A. Jemal,et al.  Breast cancer statistics, 2013 , 2014, CA: a cancer journal for clinicians.

[110]  Ting Zhou,et al.  Kinase selectivity potential for inhibitors targeting the ATP binding site: a network analysis , 2010, Bioinform..

[111]  Yong Zhou,et al.  Roll: a new algorithm for the detection of protein pockets and cavities with a rolling probe sphere , 2010, Bioinform..

[112]  Mindy I. Davis,et al.  A quantitative analysis of kinase inhibitor selectivity , 2008, Nature Biotechnology.

[113]  B. Hirst,et al.  The ABCs of drug transport in intestine and liver: efflux proteins limiting drug absorption and bioavailability. , 2004, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[114]  A. Andres,et al.  Altered mammary epithelial development, pattern formation and involution in transgenic mice expressing the EphB4 receptor tyrosine kinase. , 2002, Journal of cell science.

[115]  C. Chuong,et al.  Article type Software , 2007 .